We reviewed the relationship of serum NfL with and the dynamics of axonal injury in various immune-mediated peripheral neuropathies (such as Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy), hereditary peripheral neuropathy, drug-induced peripheral neuropathies and diabetic peripheral neuropathy, and drew a conclusion after a comprehensive analysis: the quantified NfL may be used as a promising biomarker to monitor disease activity, assess short-and long-term prognosis, and also as a potential biomarker for clinical trials and monitoring treatment response.
Sun, Xiaoling; Huang, Kaiwei; and Wan, Xinbei
"Value of Neurofilament Light Chain as a Biomarker in Peripheral Neuropathy,"
General Practice in China: Vol. 1:
2, Article 10.
Available at: https://www.gpinchina.net/journal/vol1/iss2/10